Investigating the neuroprotective effect of Donepezil in patients affected by Alzheimer disease: a 12 month longitudinal analysis of the peripheral levels of neurotrophins and inflammatory factors in first-diagnosis patients - Donepezil effects on neurotrophins and cytokines

FONDAZIONE SANTA LUCIA0 个研究点开始时间: 2010年3月23日最近更新: 2012年4月3日

适应症

试验速览

暂无简介。

•1) AD diagnosis, according to the criteria of DSM-IV and NINCDS-ADRDA; 2) MMSE score < 26 and >16; 3) To be in health and to walk independently or with the aid of a support; 4) Vision and hearing sufficient for compliance with testing procedures; 5) Laboratory values within the appropriate reference intervals or considered to be clinically insignificant by the investigators
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1) Lack of an appropriate caregiver; 2) Major medical illnesses; 3) Comorbidity of primary psychiatric or neurological disorders; 4) Evidence of focal parenchymal abnormalities at CT or MRI (AD-vascular dementia mixed forms might be included only if the vascular component doesn`t dominate the clinical picture or if a stroke is not present); Hachinski Ischemic Score≤ 4.

发起方